Legionnaires' disease is a severe form of atypical pneumonia caused by the Legionella pneumophila bacteria. Through our cutting-edge vaccine development strategies and our pioneering therapeutic approaches, we are confident in our ability to deliver transformative solutions.
Introduction to Legionnaires' Disease
Legionnaires' disease is a severe form of pneumonia caused by the gram-negative, aerobic bacterium Legionella pneumophila. This pathogen primarily thrives in artificial aquatic environments, where it can take advantage of stagnant water systems to proliferate and disseminate through aerosolized water droplets. Inhaling these contaminated microdroplets leads to infection in the human lung, resulting in a potentially life-threatening respiratory illness.
Fig.1 Constructed vaccine figure with adjuvants and linkers. (Umar A., et al., 2022)
Vaccine Development for Legionnaires' Disease
The development of a vaccine against Legionnaires' disease has been a significant focus within the scientific community. The absence of an authorized multiepitope vaccine has prompted researchers to explore various strategies, including the use of immunoinformatics and subtractive proteomic techniques.
Immunoinformatics Approach
Immunoinformatics has played a pivotal role in predicting B and T cell epitopes from potential vaccine candidate proteins. The use of bioinformatics tools has accelerated the identification of antigenic epitopes, streamlining the selection process for vaccine development.
Multiepitope Vaccine Design
The multiepitope-based vaccine (MEBV) construct is created by linking cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL), and B lymphocyte (LBL) epitopes, which are predicted to have high antigenicity and immunogenicity.
Therapeutics Development for Legionnaires' Disease
The primary therapeutics for Legionnaires' disease remains antibiotics, with fluoroquinolones, azithromycin, and doxycycline being the recommended agents. However, the emergence of antibiotic resistance has necessitated the development of new therapeutic strategies. In vitro studies suggest a synergistic effect when combining different antibiotics, such as macrolides and quinolones, indicating potential benefits in using combination therapies for severe cases of Legionnaires' disease.
With a world-class platform, our company is able to provide customers with one-stop Legionnaires' disease therapy development solutions. You can click on the link below to learn more.
Our Services
By combining our deep scientific expertise, state-of-the-art technologies, and unwavering commitment to innovation, we are poised to make a significant impact in the prevention and therapeutics of this life-threatening respiratory illness. Our capabilities span the entire drug and vaccine development spectrum, from early-stage drug discovery to preclinical research.
- Guinea Pig Models: injection of homogenized human lung samples into the peritoneum of guinea pigs
- Mouse Models: a strain mice (A/J) or genetically modified mice
Our state-of-the-art preclinical research facilities are equipped with the latest technologies and expertise to support the development of Legionnaires' Disease therapeutics and vaccines. If our services have piqued your interest, we warmly welcome you to reach out to us for further information and to obtain a detailed quotation for the services you require.
References
- Umar Ahitsham, et al. "Vaccinomics to Design a Multiepitope Vaccine against Legionella pneumophila." BioMed Research International 2022.1 (2022): 4975721.
- Viasus Diego, et al. "Legionnaires' disease: update on diagnosis and treatment." Infectious Diseases and Therapy 11.3 (2022): 973-986.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
